Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS)
can be prevented with highly active antiretroviral therapy (HAART). However, HIV-infected
people must remain on treatment continuously to avoid viral rebound and progression to AIDS.
HIV persistence is thought to stem primarily from the presence of integrated copies of the
proviral genome within long-lived cells. Because active viral gene expression causes cell
death due to viral cytopathic effects and the immune response, long-lived cells likely harbor
transcriptionally silent, latent provirus. HIV-1 persistence in long-lived cellular
reservoirs remains a major barrier to a cure. HDACi have the potential to activate ("Kick")
these latently infected cells. This will make the HIV infected cells visible to the immune
system; the immune response and antiretrovirals(ARVs) will be able to attack and eliminate
("Kill") the infected cells. This study is subsequent to our NCT02513901. The purpose of this
study is to verify the efficacy of multi-dose Chidamide in combination with antiretroviral
therapy in HIV-infected adults with suppressed viral load in a randomized controlled clinical
trial.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tang-Du Hospital
Collaborators:
Chipscreen Biosciences, Ltd. First Affiliated Hospital of Guangxi Medical University Zhejiang University